NCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
Clinical Trials
35 trialsNCT06638307 2026-04-13
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Recruiting
NCT03850873 2026-04-09
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT06486883 2026-04-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT07274709 2026-03-11
Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases
Brigham and Women's Hospital
Completed
NCT07225790 2026-02-27
Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases
Brigham and Women's Hospital
Completed
NCT05424068 2026-02-25
Rehabilitation for People With Advanced Cancer
University Health Network, Toronto
Phase NA Completed
NCT07428655 2026-02-24
Acceptability and Feasibility of PSC Model of Serious Illness Communication
National Cancer Centre, Singapore
Phase NA Active not recruiting
NCT07427394 2026-02-23
SERENA-1b
AstraZeneca
Phase 2 Not yet recruiting
NCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT06301438 2026-02-03
Dalpiciclib in HR+/HER2- ABC
RenJi Hospital
Recruiting
NCT07178743 2026-01-30
Emulation of the PALOMA-2 Trial
Brigham and Women's Hospital
Active not recruiting
NCT07359404 2026-01-22
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Enrolling by invitation
NCT06612203 2025-12-05
WIN-B
MedSIR
Phase 1/2 Active not recruiting
NCT07259226 2025-12-02
OASIS
UNICANCER
Phase 2 Recruiting
NCT05530057 2025-11-20
ESPERO
Seoul National University Hospital
Phase 2 Recruiting
NCT05831878 2025-11-18
RC48-ADC in HER2-low Advanced Breast Cancer
RenJi Hospital
Phase NA Recruiting
NCT07130383 2025-11-18
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 2 Recruiting
NCT07180082 2025-11-18
CORIN-PYRA
RenJi Hospital
Phase 2 Recruiting
NCT07180160 2025-11-18
ITHRAN
RenJi Hospital
Phase 2 Recruiting
NCT07180264 2025-11-18
Trastuzumab Deruxtecan in Advanced Breast Cancer
RenJi Hospital
Recruiting
NCT07173556 2025-09-15
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05876065 2025-09-11
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
RenJi Hospital
Phase NA Recruiting
NCT07125950 2025-08-15
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT07101601 2025-08-03
Study of DM5167 in Patients With Advanced Solid Tumors
DIGMBIO
Phase 1 Recruiting
NCT04227327 2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2 Terminated
NCT05173103 2025-07-25
HERMIONE-13
University of Milano Bicocca
Completed
NCT06500494 2025-07-24
VINOREAL
Pierre Fabre Medicament
Recruiting
NCT07083505 2025-07-24
A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT07041437 2025-06-27
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06941142 2025-04-23
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT04892693 2025-04-17
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Seoul National University Hospital
Phase 2 Recruiting
NCT05536128 2025-04-17
Post-CDK
Seoul National University Hospital
Phase 2 Recruiting